NCI-H522 Cells

The NCI-H522 cell line is derived from a human non-small cell lung carcinoma (NSCLC), specifically an adenocarcinoma, of an adult patient. This cell line is extensively used in lung cancer research, offering a model to study the molecular and cellular mechanisms underlying adenocarcinoma, the most common subtype of NSCLC. NCI-H522 cells are valuable for investigating genetic mutations, signal transduction pathways, and therapeutic responses associated with lung adenocarcinoma.
NCI-H522 cells exhibit an epithelial morphology and express markers characteristic of lung adenocarcinoma, including cytokeratins and carcinoembryonic antigen (CEA). They harbor genetic alterations frequently observed in NSCLC, such as mutations in the TP53 gene and deletions in the RB1 gene. Researchers utilize NCI-H522 cells to explore key signaling pathways involved in lung cancer progression, such as the EGFR, KRAS, and PI3K/Akt pathways. These cells are also employed in high-throughput drug screening assays and preclinical testing of chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, NCI-H522 cells are used to study mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the NCI-H522 cell line in lung adenocarcinoma research highlights its importance in advancing our understanding of lung cancer biology and in the development of new and more effective treatment approaches for patients with NSCLC.